Biotech | October 07, 2021
Moderna to build mRNA facility in Africa
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
The collaboration will support Canada with direct access to rapid pandemic response capabilities
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Subscribe To Our Newsletter & Stay Updated
